U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s Macroglobulinemia

BeiGene Ltd. Announces a new approval for BRUKINSA (zanubrutinib) in Waldenström’s macroglobulinaemia, including the updated Prescribing Information.

For more information:

Download BRUKINSA Full Prescribing Information

Download BRUKINSA Patient Information

BRUKINSA WEBSITE



No comments have been posted yet.